Pliant Therapeutics, Inc.
PLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $32 | $43 | $39 |
| G&A Expenses | $10 | $13 | $15 | $15 |
| SG&A Expenses | $10 | $13 | $15 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $28 | $45 | $59 | $53 |
| Operating Income | -$28 | -$46 | -$59 | -$53 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $4 |
| Pre-Tax Income | -$26 | -$43 | -$56 | -$50 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$43 | -$56 | -$50 |
| % Margin | – | – | – | – |
| EPS | -0.43 | -0.71 | -0.92 | -0.82 |
| % Growth | 39.4% | 22.8% | -12.2% | – |
| EPS Diluted | -0.43 | -0.71 | -0.92 | -0.82 |
| Weighted Avg Shares Out | 61 | 61 | 61 | 61 |
| Weighted Avg Shares Out Dil | 61 | 61 | 61 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $4 | $4 |
| Interest Expense | $3 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$42 | -$55 | -$48 |
| % Margin | – | – | – | – |